Anti-Inflammatory Therapeutics Market Size, Share, Growth, 2034

Table Of Content

Executive Summary

Research Scope & Segmentation

Research Objectives
Limitations & Assumptions
Market Scope & Segmentation
Currency & Pricing Considered

Market Opportunity Assessment

Emerging Regions / Countries
Emerging Companies
Emerging Applications / End Use

Market Trends

Drivers
Market Warning Factors
Latest Macro Economic Indicators
Geopolitical Impact
Technology Factors

Market Assessment

Porters Five Forces Analysis
Value Chain Analysis

Regulatory Framework

North America
Europe
APAC
Middle East and Africa
LATAM

ESG Trends

Global Anti-Inflammatory Therapeutics Market Size Analysis

Global Anti-Inflammatory Therapeutics Market Introduction
By Drug Class
1. Introduction
  1. Drug Class By Value
2. Anti-inflammatory Biologics
  1. By Value
3. Non-steroidal Anti-inflammatory Drugs (NSAIDs)
  1. By Value
4. Corticosteroids
  1. By Value
By Indication
1. Introduction
  1. Indication By Value
2. Arthritis
  1. By Value
3. Anti-inflammatory Bowel Disease (IBD)
  1. By Value
4. Respiratory Disease
  1. By Value
5. Multiple Sclerosis
  1. By Value
6. Psoriasis
  1. By Value
7. Others
  1. By Value
By Distribution Channel
1. Introduction
  1. Distribution Channel By Value
2. Hospital Pharmacies
  1. By Value
3. Retail Pharmacies
  1. By Value
4. Online Providers
  1. By Value

North America Market Analysis

Introduction
By Drug Class
1. Introduction
  1. Drug Class By Value
2. Anti-inflammatory Biologics
  1. By Value
3. Non-steroidal Anti-inflammatory Drugs (NSAIDs)
  1. By Value
4. Corticosteroids
  1. By Value
By Indication
1. Introduction
  1. Indication By Value
2. Arthritis
  1. By Value
3. Anti-inflammatory Bowel Disease (IBD)
  1. By Value
4. Respiratory Disease
  1. By Value
5. Multiple Sclerosis
  1. By Value
6. Psoriasis
  1. By Value
7. Others
  1. By Value
By Distribution Channel
1. Introduction
  1. Distribution Channel By Value
2. Hospital Pharmacies
  1. By Value
3. Retail Pharmacies
  1. By Value
4. Online Providers
  1. By Value
U.S.
1. By Drug Class
  1. Introduction
    1. Drug Class By Value
  2. Anti-inflammatory Biologics
    1. By Value
  3. Non-steroidal Anti-inflammatory Drugs (NSAIDs)
    1. By Value
  4. Corticosteroids
    1. By Value
2. By Indication
  1. Introduction
    1. Indication By Value
  2. Arthritis
    1. By Value
  3. Anti-inflammatory Bowel Disease (IBD)
    1. By Value
  4. Respiratory Disease
    1. By Value
  5. Multiple Sclerosis
    1. By Value
  6. Psoriasis
    1. By Value
  7. Others
    1. By Value
3. By Distribution Channel
  1. Introduction
    1. Distribution Channel By Value
  2. Hospital Pharmacies
    1. By Value
  3. Retail Pharmacies
    1. By Value
  4. Online Providers
    1. By Value
Canada

Europe Market Analysis

Introduction
By Drug Class
1. Introduction
  1. Drug Class By Value
2. Anti-inflammatory Biologics
  1. By Value
3. Non-steroidal Anti-inflammatory Drugs (NSAIDs)
  1. By Value
4. Corticosteroids
  1. By Value
By Indication
1. Introduction
  1. Indication By Value
2. Arthritis
  1. By Value
3. Anti-inflammatory Bowel Disease (IBD)
  1. By Value
4. Respiratory Disease
  1. By Value
5. Multiple Sclerosis
  1. By Value
6. Psoriasis
  1. By Value
7. Others
  1. By Value
By Distribution Channel
1. Introduction
  1. Distribution Channel By Value
2. Hospital Pharmacies
  1. By Value
3. Retail Pharmacies
  1. By Value
4. Online Providers
  1. By Value
U.K.
1. By Drug Class
  1. Introduction
    1. Drug Class By Value
  2. Anti-inflammatory Biologics
    1. By Value
  3. Non-steroidal Anti-inflammatory Drugs (NSAIDs)
    1. By Value
  4. Corticosteroids
    1. By Value
2. By Indication
  1. Introduction
    1. Indication By Value
  2. Arthritis
    1. By Value
  3. Anti-inflammatory Bowel Disease (IBD)
    1. By Value
  4. Respiratory Disease
    1. By Value
  5. Multiple Sclerosis
    1. By Value
  6. Psoriasis
    1. By Value
  7. Others
    1. By Value
3. By Distribution Channel
  1. Introduction
    1. Distribution Channel By Value
  2. Hospital Pharmacies
    1. By Value
  3. Retail Pharmacies
    1. By Value
  4. Online Providers
    1. By Value
Germany
France
Spain
Italy
Russia
Nordic
Benelux
Rest of Europe

APAC Market Analysis

Introduction
By Drug Class
1. Introduction
  1. Drug Class By Value
2. Anti-inflammatory Biologics
  1. By Value
3. Non-steroidal Anti-inflammatory Drugs (NSAIDs)
  1. By Value
4. Corticosteroids
  1. By Value
By Indication
1. Introduction
  1. Indication By Value
2. Arthritis
  1. By Value
3. Anti-inflammatory Bowel Disease (IBD)
  1. By Value
4. Respiratory Disease
  1. By Value
5. Multiple Sclerosis
  1. By Value
6. Psoriasis
  1. By Value
7. Others
  1. By Value
By Distribution Channel
1. Introduction
  1. Distribution Channel By Value
2. Hospital Pharmacies
  1. By Value
3. Retail Pharmacies
  1. By Value
4. Online Providers
  1. By Value
China
1. By Drug Class
  1. Introduction
    1. Drug Class By Value
  2. Anti-inflammatory Biologics
    1. By Value
  3. Non-steroidal Anti-inflammatory Drugs (NSAIDs)
    1. By Value
  4. Corticosteroids
    1. By Value
2. By Indication
  1. Introduction
    1. Indication By Value
  2. Arthritis
    1. By Value
  3. Anti-inflammatory Bowel Disease (IBD)
    1. By Value
  4. Respiratory Disease
    1. By Value
  5. Multiple Sclerosis
    1. By Value
  6. Psoriasis
    1. By Value
  7. Others
    1. By Value
3. By Distribution Channel
  1. Introduction
    1. Distribution Channel By Value
  2. Hospital Pharmacies
    1. By Value
  3. Retail Pharmacies
    1. By Value
  4. Online Providers
    1. By Value
Korea
Japan
India
Australia
Taiwan
South East Asia
Rest of Asia-Pacific

Middle East and Africa Market Analysis

Introduction
By Drug Class
1. Introduction
  1. Drug Class By Value
2. Anti-inflammatory Biologics
  1. By Value
3. Non-steroidal Anti-inflammatory Drugs (NSAIDs)
  1. By Value
4. Corticosteroids
  1. By Value
By Indication
1. Introduction
  1. Indication By Value
2. Arthritis
  1. By Value
3. Anti-inflammatory Bowel Disease (IBD)
  1. By Value
4. Respiratory Disease
  1. By Value
5. Multiple Sclerosis
  1. By Value
6. Psoriasis
  1. By Value
7. Others
  1. By Value
By Distribution Channel
1. Introduction
  1. Distribution Channel By Value
2. Hospital Pharmacies
  1. By Value
3. Retail Pharmacies
  1. By Value
4. Online Providers
  1. By Value
UAE
1. By Drug Class
  1. Introduction
    1. Drug Class By Value
  2. Anti-inflammatory Biologics
    1. By Value
  3. Non-steroidal Anti-inflammatory Drugs (NSAIDs)
    1. By Value
  4. Corticosteroids
    1. By Value
2. By Indication
  1. Introduction
    1. Indication By Value
  2. Arthritis
    1. By Value
  3. Anti-inflammatory Bowel Disease (IBD)
    1. By Value
  4. Respiratory Disease
    1. By Value
  5. Multiple Sclerosis
    1. By Value
  6. Psoriasis
    1. By Value
  7. Others
    1. By Value
3. By Distribution Channel
  1. Introduction
    1. Distribution Channel By Value
  2. Hospital Pharmacies
    1. By Value
  3. Retail Pharmacies
    1. By Value
  4. Online Providers
    1. By Value
Turkey
Saudi Arabia
South Africa
Egypt
Nigeria
Rest of MEA

LATAM Market Analysis

Introduction
By Drug Class
1. Introduction
  1. Drug Class By Value
2. Anti-inflammatory Biologics
  1. By Value
3. Non-steroidal Anti-inflammatory Drugs (NSAIDs)
  1. By Value
4. Corticosteroids
  1. By Value
By Indication
1. Introduction
  1. Indication By Value
2. Arthritis
  1. By Value
3. Anti-inflammatory Bowel Disease (IBD)
  1. By Value
4. Respiratory Disease
  1. By Value
5. Multiple Sclerosis
  1. By Value
6. Psoriasis
  1. By Value
7. Others
  1. By Value
By Distribution Channel
1. Introduction
  1. Distribution Channel By Value
2. Hospital Pharmacies
  1. By Value
3. Retail Pharmacies
  1. By Value
4. Online Providers
  1. By Value
Brazil
1. By Drug Class
  1. Introduction
    1. Drug Class By Value
  2. Anti-inflammatory Biologics
    1. By Value
  3. Non-steroidal Anti-inflammatory Drugs (NSAIDs)
    1. By Value
  4. Corticosteroids
    1. By Value
2. By Indication
  1. Introduction
    1. Indication By Value
  2. Arthritis
    1. By Value
  3. Anti-inflammatory Bowel Disease (IBD)
    1. By Value
  4. Respiratory Disease
    1. By Value
  5. Multiple Sclerosis
    1. By Value
  6. Psoriasis
    1. By Value
  7. Others
    1. By Value
3. By Distribution Channel
  1. Introduction
    1. Distribution Channel By Value
  2. Hospital Pharmacies
    1. By Value
  3. Retail Pharmacies
    1. By Value
  4. Online Providers
    1. By Value
Mexico
Argentina
Chile
Colombia
Rest of LATAM

Competitive Landscape

Anti-Inflammatory Therapeutics Market Share By Players
M&A Agreements & Collaboration Analysis

Market Players Assessment

Eli Lilly and Company
1. Overview
2. Business Information
3. Revenue
4. ASP
5. SWOT Analysis
6. Recent Developments
F. Hoffmann-La Roche AG
Pfizer Inc.
GSK
Johnson & Johnson Services, Inc.
Novartis AG
AstraZeneca PLC
Amgen Inc.
Merck & Co., Inc.
Ferring Pharmaceuticals
Bioventus LLC
Zimmer Biomet Holdings, Inc.
Flexion Therapeutics, Inc.
Bayer AG
Dr. Reddy’s Laboratories Ltd

Research Methodology

Research Data
1. Secondary Data
  1. Major secondary sources
  2. Key data from secondary sources
2. Primary Data
  1. Key data from primary sources
  2. Breakdown of primaries
3. Secondary And Primary Research
  1. Key industry insights
Market Size Estimation
1. Bottom-Up Approach
2. Top-Down Approach
3. Market Projection
Research Assumptions
1. Assumptions
Limitations
Risk Assessment

Appendix

Discussion Guide
Customization Options
Related Reports

Disclaimer

Get This Report

Our Clients:

Hindustan National Glass & Industries Limited

Table Of Content

Download Free Sample

Debashree B

Healthcare Lead